FDAnews
www.fdanews.com/articles/98300-japan-rsquo-s-national-institute-of-infectious-diseases-widens-research-on-ampligen

Japan’s National Institute of Infectious Diseases Widens Research on Ampligen

September 11, 2007

Hemispherx Biopharma announced that Japan’s National Institute of Infectious Diseases has extended its relationship with the company to initiate research on the intranasal co-administration of the National Institute of Infectious Diseases’ HIV-1 vaccine with Hemispherx’s experimental TLR3 agonist and immune enhancer, Ampligen.

Ampligen, an experimental immunotherapeutic, will be combined with HIV recombinant protein and administered intranasally. Once antibodies are produced, the National Institute of Infectious Diseases will further analyze neutralizing and protective activity, Hemispherx said.

The company is preparing a new drug application to be submitted to the FDA for the use of Ampligen as a prospective monotherapy for chronic fatigue syndrome.